Data on Wilson’s Disease Reported by Thomas Daniel-Robin and Colleagues (Epidemiology, treatment and burden of Wilson Disease in France: a 10-year analysis of the National Health Insurance Database): Nutritional and Metabolic Diseases and Conditions – Wilson’s Disease

2022 JUL 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Business Daily -- New research on Nutritional and Metabolic Diseases and Conditions - Wilson’s Disease is the subject of a report. According to news reporting from Paris, France, by NewsRx journalists, research stated, “Wilson disease (WD) is a rare hereditary, debilitating disease that is fatal if untreated. Given its low prevalence, collecting longitudinal information on large cohorts of patients is challenging.”

The news correspondents obtained a quote from the research, “Analysis of health insurance databases offers an approach to meet this challenge. The aim of this study was to evaluate longitudinal trends in the presentation and management of patients with WD identified in the French national health insurance database (SNDS). This retrospective, longitudinal, observational study identified people with WD in the SNDS database through hospitalisation diagnosis codes and long-term illness status between 2009 and 2019 inclusive. For each patient, data were extracted on hospitalisations, liver transplantation, mortality, WD-specific treatments (d-penicillamine, trientine and zinc), disability status and sick leave. 1,928 patients with WD were identified, of whom 1,520 (78.8%) were analysed. Prevalence of WD in 2019 was estimated as 2.2 cases per 100,000. Of the 670 patients first documented between 2010 and 2019, 76.1% were hospitalised at least once for a mean duration of 4.63±10.6 days. 152 patients (10.0%) underwent liver transplantation and 205 died (13.5%). The mean age at death was 57.9±23.1 years. 665 patients (43.8%) received a WD-specific treatment at least once. 167 patients (17.1%) received a government disability pension and 624 (41.1%) benefited from long-term illness status due to WD. Unexpectedly, less than half of patients with WD received treatment recommended in practice guidelines, which may contribute to a high disease burden in terms of hospitalisations, disability and reduced life expectancy.”

According to the news reporters, the research concluded: “Improving treatment rates, building patient awareness of long-term disease impact or developing a new paradigm of treatment could make a significant contribution to reducing the disease burden.”

This research has been peer-reviewed.

For more information on this research see: Epidemiology, treatment and burden of Wilson Disease in France: a 10-year analysis of the National Health Insurance Database. Clinics and Research in Hepatology and Gastroenterology, 2022:101992. Clinics and Research in Hepatology and Gastroenterology can be contacted at: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France. (Elsevier - www.elsevier.com; Clinics and Research in Hepatology and Gastroenterology - http://www.journals.elsevier.com/clinics-and-research-in-hepatology-and-gastroenterology/)

Our news journalists report that additional information may be obtained by contacting Thomas Daniel-Robin, Vivet Therapeutics, Paris, France. Additional authors for this research include Bernard Benichou, Claire Leboucher, Cecile Blein and Jean-Philippe Combal.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clinre.2022.101992. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Clinics and Research in Hepatology and Gastroenterology is: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France.

(Our reports deliver fact-based news of research and discoveries from around the world.)